PureTech established the underlying programs and platforms that resulted in 29 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including three taken from inception at PureTech to FDA approval.
PureTech established the underlying programs and platforms that resulted in 28 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.

Internal Programs

Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis
100% Equity
Phase 2 completed
See Our Program
1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

Founded Entities1

Neuropsychiatric conditions
35.6% Equity
Phase 2
See Our Program
Cobenfy™ (formerly known as KarXT) Now FDA Approved for the Treatment of Schizophrenia in Adults
Milestone Payments/ Royalties & up to $400M in milestone payments from agreement w/Royalty Pharma2
FDA Approved
See Our Program
Pioneering a new category of oral therapies based on defined bacterial consortia
35.8% Equity
Phase 3
See Our Program
Hematological malignancies, such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and locally advanced/metastatic solid tumors, including head and neck cancers
100% Equity
Phase 1/2
See Our Program
Engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers
2.1% Equity
Phase 1/2a
See Our Program
Engineering hydrogels to enable the oral administration of peptide therapeutics (e.g., GLP-1 agonists)
73.8% Equity
Preclinical
See Our Program
A voice-based artificial intelligence platform to detect changes in health
34.9% Equity
Commercial Release
See Our Program

COBENFY™ (xanomeline and trospium chloride) is indicated for the treatment of schizophrenia in adults. For Important Safety Information, see U.S. Full Prescribing Information, including Patient Information on COBENFY.com.
Note: PureTech retains control of Entrega, Inc. and Seaport Therapeutics, and they are consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc.
1 Relevant ownership interests were calculated on a partially diluted basis (as opposed to a voting basis) as of June 30, 2024, and Seaport as of October 18, 2024, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Gallop Oncology, Inc. Vor Biopharma ownership was calculated on a beneficial ownership basis in accordance with SEC rules as of March 13, 2025. 2 As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.

PureTech Level Cash, Cash Equivalents & Short-Term Investments

$400.6M
PureTech Level Cash, Cash Equivalents and Short-Term Investments
as of June 30, 20243

3 PureTech Level Cash, cash equivalents and short-term investments is a Non-IFRS measure.

Developing breakthrough medicines at PureTech